Teyame 360 S.L. Reports Profitable 2025 Results and Announces Acquisition by Healthcare Triangle, Inc.

Key Highlights for Investors

• Profitable Year: Teyame 360 S.L. delivered a net profit of \$1.10 million for the year ended December 31, 2025, marking its second consecutive year of profitability.
• Strong Revenue Base: The company generated \$17.16 million in net revenue for 2025, reflecting a stable top line compared to the previous year (\$17.92 million in 2024).
• Acquisition Announcement: On January 29, 2026, Teyame 360 S.L. entered into a Share Purchase Agreement to sell 100% of its equity to Teyame AI LLC, assignable to Healthcare Triangle, Inc. This is a significant development that could impact share valuations and future strategy.
• Improving Financial Position: Shareholders’ equity more than doubled to \$2.43 million at year-end 2025, up from \$1.07 million in 2024, reflecting both retained earnings growth and favorable currency translation adjustments.
• Reduction in Long-term Debt: The company made significant repayments, reducing long-term debt to \$367,284 from \$2.18 million, and shifting some obligations to short-term borrowings (\$3.44 million at year-end 2025).
• Increased Accounts Receivable: Accounts receivable grew sharply to \$4.74 million, signaling robust business activity, although this could also flag potential collection risks.
• No Critical Audit Matters: The independent auditors reported no critical audit matters, suggesting clean financial reporting and no significant accounting concerns.
• Functional Currency and Reporting: The company’s functional currency is the euro, but results are reported in US dollars. This has led to notable foreign currency translation gains recognized in equity.

Detailed Financial Review

Income Statement Overview

• Net Revenue: \$17.16 million in 2025, slightly down from \$17.92 million in 2024, but still reflecting a stable revenue base.
• Cost of Revenue: \$9.26 million in 2025, down from \$9.94 million, leading to an improved gross margin.
• Operating Expenses: \$6.23 million in 2025, including \$5.35 million in SG&A and \$883,000 in depreciation/amortization. Operating expenses declined slightly year-on-year.
• Profit from Operations: \$1.67 million in 2025, up from \$1.60 million in 2024.
• Interest Expense: \$214,481 in 2025, down from \$276,189 in 2024, reflecting lower debt levels.
• Income Tax: \$361,670 in 2025, a substantial increase from \$55,180, due to higher pre-tax profit and possibly reduced deferred tax benefits.
• Net Profit: \$1.10 million, compared to \$1.27 million in 2024.
• EPS: Reported at \$10.01 per share (basic and diluted), down from \$11.55 in 2024, with 110,302 shares outstanding.

Balance Sheet Strength

• Total Assets: \$10.17 million as of December 31, 2025 (up from \$6.71 million in 2024).
• Current Assets: \$5.77 million, including a significant increase in accounts receivable.
• Property & Equipment: \$1.49 million, down from \$1.85 million, reflecting ongoing depreciation and limited new capital expenditure.
• Intangible Assets: \$2.22 million, up from \$995,317, largely from ongoing research & development capitalization and software investments.
• Liabilities: Total liabilities rose to \$7.74 million, with a marked increase in short-term borrowings and accounts payable, partially offset by a reduction in long-term debt.
• Equity: Shareholders’ equity increased to \$2.43 million, reflecting both profit retention and positive foreign currency translation adjustments (\$158,720 in accumulated other comprehensive income, versus a deficit in 2024).

Cash Flow Insights

• Operating Cash Flow: \$2.19 million net cash provided by operating activities, down from \$3.30 million in 2024, primarily due to working capital changes (notably increased receivables).
• Investing Cash Flow: Net outflow of \$1.49 million, mainly from investment in intangible assets and property, plant, and equipment.
• Financing Cash Flow: Net outflow of \$696,000, with debt repayment and changes in other long-term liabilities.
• Ending Cash Balance: \$1,796 as of December 31, 2025, up slightly from \$446 in 2024, indicating a minimal cash buffer.

Segment/Business Model and Services

• Teyame 360 S.L. operates in advertising, marketing, public relations, and telecommunications, with a focus on technology-enabled contact center and telemarketing services.
• The company provides a diversified service set including customer acquisition, sales conversion, appointment setting, support, collections, commercial outreach, and CRM, leveraging a 360-degree campaign management model.
• Clients are primarily based in Spain, with the company using geographically distributed teams and multi-channel engagement strategies.

Critical and Price-Sensitive Information for Shareholders

• Acquisition by Healthcare Triangle, Inc.:
  • Teyame 360 S.L. has agreed to sell 100% of its equity to Teyame AI LLC (assignable to Healthcare Triangle, Inc.), as announced in a Share Purchase Agreement dated January 29, 2026.
  • This is a major, potentially price-sensitive event—shareholders should anticipate possible changes in ownership structure, governance, and strategic direction.
  • The transaction is classified as a non-adjusting subsequent event; no changes have been made to the 2025 year-end financials as a result. However, the deal could reshape the company’s competitive positioning and value proposition in upcoming periods.
• Financial Stability and Growth:
  • Sustained profitability and balance sheet improvement may attract further investor interest and support higher valuations.
  • Growing receivables and reduced long-term debt indicate both robust sales and improved financial discipline, but also suggest close monitoring of credit risk is warranted.
• No Critical Audit Matters:
  • Auditors found no critical issues, which may enhance investor confidence in the company’s financial reporting.
• Currency Translation Gains:
  • Foreign currency translation added significantly to equity; this may fluctuate in future periods depending on EUR/USD movements.

Other Noteworthy Details

• The company capitalized \$1.23 million in new intangible assets during the year, mainly R&D and software, underscoring ongoing investment in innovation.
• There are no allowances for doubtful accounts as of December 31, 2025, but the sharp increase in receivables merits investor attention regarding collection risk.
• Short-term borrowings rose mainly due to reclassification of debt due within one year, not new borrowing, which is relevant for liquidity analysis in 2026.
• No material related party payables or off-balance-sheet commitments were reported.

Conclusion

This report is highly relevant for investors. The profitable 2025 results, balance sheet improvement, and—most importantly—the planned sale to Healthcare Triangle, Inc. represent significant, potentially price-moving developments. The acquisition is likely to drive a re-rating of the company’s valuation and could lead to strategic changes post-transaction. Investors should closely monitor further disclosures regarding the closing of the acquisition and any integration plans or management changes.

Disclaimer

This article is based on audited financial statements and public filings as of December 31, 2025, and related subsequent events. It does not constitute investment advice. Investors are strongly encouraged to review all company disclosures and consult their financial advisors prior to making investment decisions. The forward-looking impact of the announced acquisition and ongoing financial performance is subject to change based on future events and market conditions.

View Healthcare Triangle, Inc. Historical chart here